There is minimal clinical experience with overdose. During clinical trials, two patients diagnosed with ATTR-CM accidentally ingested a single tafamidis meglumine dose of 160 mg without adverse events. The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose.
For management of a suspected drug overdose, contact your regional poison control centre.
VYNDAMAX (tafamidis) is indicated for:
Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (≥65 years of age): Safety and efficacy were demonstrated in this population.
VYNDAMAX (tafamidis) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
VYNDAMAX (tafamidis) capsules and VYNDAQEL (tafamidis meglumine) capsules are different formulations with the active moiety tafamidis. To avoid dosing errors, it is important that prescriptions of tafamidis/tafamidis meglumine specify the salt form and the prescribed dose. VYNDAMAX and VYNDAQEL are not interchangeable on a per mg basis (see 10.3 Pharmacokinetics, Section 14.3 Comparative Bioavailability Studies and the Product Monograph for VYNDAQEL).
The recommended dose of VYNDAMAX (tafamidis) is 61 mg tafamidis (administered as one 61‑mg tafamidis capsule) orally once daily.
The recommended dose of VYNDAQEL (tafamidis meglumine) is 80 mg administered as 4 x 20 mg tafamidis meglumine capsules (equivalent to 48.8 mg tafamidis) orally once daily.
The dose may be reduced to one capsule of 20 mg VYNDAQEL (tafamidis meglumine) (equivalent to 12.2 mg of tafamidis) if not tolerated (see 14 Clinical Trials section and also Product Monograph for VYNDAQEL).
VYNDAMAX should not be used during pregnancy (see 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women).
Women of childbearing potential should use appropriate contraception when taking VYNDAMAX and continue to use contraception for one month after stopping treatment.
Pediatrics (<18 years of age)
VYNDAMAX is not indicated in the pediatric population.
Geriatrics (≥65 years of age)
No dosage adjustment is required for elderly patients (≥65 years). Of the total number of patients receiving tafamidis meglumine in the ATTR-CM clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.
Renal or hepatic impairment
VYNDAMAX has not been studied in patients with severe hepatic impairment and use is not recommended in these patients. No dosage adjustment is required for patients with mild or moderate hepatic impairment. Data are limited in patients with severe renal impairment. No dosage adjustment is required for patients with renal impairment.
The capsule(s) should be swallowed whole and not crushed or cut. VYNDAMAX may be taken with or without food.
If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.
Route of Administration
Dosage Form / Strength/Composition
VYNDAMAX (tafamidis) 61 mg: reddish brown, opaque, oblong (approximately 21 mm) capsule with “VYN 61” printed in white. Thirty (30) capsules (one-month supply) supplied in a carton of 3 blister cards. Each blister card contains 10 capsules.
No studies have been conducted in organ transplant patients. The efficacy and safety of VYNDAMAX (tafamidis) in organ transplant patients have not been established. VYNDAMAX is not recommended in these patients.
Carcinogenesis and Mutagenesis
There was no evidence of an increased incidence of neoplasia in the transgenic (Tg)‑rasH2 mouse following repeated daily administration of tafamidis meglumine for 26 weeks at daily doses of 0, 10, 30 or 90 mg/kg. There was no evidence of increased incidence of neoplasia in a 2‑year carcinogenicity study in rats at exposures 18‑times the human Area Under Curve (AUC) at the clinical dose of 61 mg tafamidis (see 16 NON-CLINICAL TOXICOLOGY).
There was no evidence of mutagenicity or clastogenicity in vitro, and an in vivo rat micronucleus study was negative.
Driving and Operating Machinery
VYNDAMAX has not been shown to influence the ability to drive and use machines.
VYNDAMAX has not been studied in patients with severe hepatic impairment and use is not recommended in these patients.
Limited data are available in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min).
Reproductive Health: Female and Male Potential
Studies in animals have shown developmental toxicity. The potential risk for humans is unknown. VYNDAMAX should not be used during pregnancy (see 16 NON-CLINICAL TOXICOLOGY).
Women of childbearing potential should use appropriate contraception when taking VYNDAMAX and continue to use contraception for 1‑month after stopping treatment.
There are no adequate and well-controlled clinical studies with the use of VYNDAMAX in pregnant women. Studies in animals have shown developmental toxicity. The potential risk for humans is unknown. VYNDAMAX should not be used during pregnancy.
There are no clinical data available to support the presence of tafamidis in human breast milk. Nonclinical data demonstrate that tafamidis is secreted in the milk of lactating rats (see 16 NON-CLINICAL TOXICOLOGY). When a drug is present in animal milk, it is likely the drug will be present in human milk. The effect of VYNDAMAX on nursing infants after administration to the mother has not been studied. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breast-fed infant, VYNDAMAX should not be used by nursing women.
Pediatrics (<18 years of age): VYNDAMAX is not indicated and should not be prescribed in the pediatric population.
Geriatrics (≥65 years of age): Safety and efficacy were demonstrated in this population.
In clinical trials, the most frequently reported Treatment Emergent Serious Adverse Events (TESAEs) in the tafamidis meglumine 80 mg, tafamidis meglumine 20 mg and placebo groups respectively were condition aggravated (22.7%, 23.9% and 32.8%); cardiac failure (19.3%, 18.2%, and 22.6%), cardiac failure congestive (11.9%, 15.9% and 17.5%), cardiac failure acute (13.1%, 4.5% and 9.6%), fall (5.1%, 5.7% and 2.8%) and syncope (3.4%, 0%, 5.6%).
Treatment Emergent Adverse Events (TEAEs) with a higher incidence in the tafamidis meglumine 80 mg and 20 mg treatment group than placebo (≥2x placebo and reported by ≥4 patients) respectively, included cystitis (3.4%, 2.3% and 0%), sinusitis (5.7%, 5.7% and 0.6%), asthenia (10.2%, 12.5% and 6.2%), balance disorder (8.5%, 2.3% and 1.1%) and cataract (5.1%, 3.4% and 1.1%).
Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.
The data across clinical trials reflect exposure of 377 ATTR‑CM patients to either 20 mg or 80 mg (administered as four 20 mg capsules) of tafamidis meglumine (VYNDAQEL) daily for an average of 24.5 months (ranging from 1 day to 111 months). Tafamidis 61 mg (VYNDAMAX) was not administered in the pivotal study. The population included adult patients diagnosed with ATTR‑CM with baseline NYHA (New York Heart Association) Class I, Class II or Class III respectively at 9.1%, 61.4%, and 29.5% in the pooled tafamidis arm and at 7.3%, 57.1% and 35.6%, respectively on placebo. The mean age was approximately 75 years (ranging from 46 years to 91 years of age); >90% were male, and approximately 82% were Caucasian (see Study Results Table 6: Patient Demographics and Baseline Characteristics).
Adverse events were assessed from ATTR‑CM clinical trials with tafamidis meglumine including a 30‑month placebo‑controlled trial in patients diagnosed with ATTR‑CM. The frequency of adverse events in patients treated with tafamidis meglumine 20 mg (n=88) or 80 mg (n=176; administered as four 20 mg capsules) was comparable to placebo (n=177). Listed below are all causality adverse events reported in the pivotal clinical trial.
A similar proportion of tafamidis meglumine‑treated patients compared to placebo discontinued due to an adverse event in the 30‑month placebo‑controlled trial in patients diagnosed with ATTR‑CM [12 (6.8%), 5 (5.7%), and 11 (6.2%)] from the tafamidis meglumine 80 mg, tafamidis meglumine 20 mg, and placebo groups, respectively].
The most commonly reported TEAEs (≥10%) in the tafamidis meglumine 80 mg and/or 20 mg groups that occurred at rates higher than placebo are as follows (Table 2).
Table 2 – Most common (≥10%) Treatment-Emergent Adverse Events reported at a higher rate in the tafamidis meglumine 80 mg and/or 20 mg groups than in the placebo group (All Causality)
System Organ Class Preferred Term
Tafamidis 20 mg
Tafamidis 80 mg
cardiac failure acute
cardiac failure congestive
General disorders and administration site conditions
Infections and infestations
Injury, poisoning and procedural complications
Musculoskeletal and connective tissue disorders
pain in extremity
Renal and urinary disorders
Respiratory, thoracic and mediastinal disorders
The reported incidence of hypothyroidism was 6.8%, 5.7% and 5.6% in patients in the tafamidis meglumine 80 mg, 20 mg and placebo groups, respectively.
The incidence of thyroxine abnormality <0.8 x LLN was greater in the tafamidis meglumine 80 mg group (29.7%) than in the tafamidis meglumine 20 mg (12.3%) and placebo (4.5%) groups. No clinically meaningful shifts in free thyroxine or thyroid stimulating hormone values were observed, and no corresponding signal in thyroid dysfunction was observed in the analysis of TEAEs (see 8.2 Clinical Trial Adverse Reactions for rates of hypothyroidism reported in clinical trials).
Low neutrophil count (<0.8 x LLN) was more frequent with tafamidis meglumine treatment than with placebo (1.9% tafamidis meglumine 80 mg, 1.2% tafamidis meglumine 20 mg, 0.6% placebo).
Elevated liver function tests were more frequent in the tafamidis meglumine 80 mg group (3.4%) than in the tafamidis meglumine 20 mg (2.3%) and placebo (1.1%) groups.
The following treatment emergent adverse drug reactions were observed in patients treated with tafamidis 61 mg:
Gastrointestinal disorders: abdominal discomfort, abdominal pain, constipation, diarrhea
Skin and subcutaneous tissue disorders: pruritus, rash
In vitro studies:
Cytochrome P450 Enzymes: Tafamidis induces CYP2B6 and CYP3A4 and does not induce CYP1A2.
Tafamidis does not inhibit cytochrome P450 enzymes CYP1A2, CYP3A4, CYP3A5, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and moderately inhibits CYP2C8.
UDP glucuronosyltransferase (UGT): Tafamidis inhibits intestinal activities of UGT1A1 but neither induces nor inhibits other UDP glucuronosyltransferase (UGT) systemically.
Transporter Systems: Tafamidis inhibits breast cancer resistant protein (BCRP).
In vitro studies and model predictions show that tafamidis has a potential to inhibit the organic anion transporters OAT1 and OAT3 at clinically relevant concentrations.
Tafamidis did not show a potential to inhibit Multi‑Drug Resistant Protein (MDR1) (also known as P‑glycoprotein; P‑gp), organic cation transporter OCT2, multidrug and toxin extrusion transporters MATE1 and MATE2K and, organic anion transporting polypeptide OATP1B1 and OATP1B3.
Transporter Systems: Tafamidis inhibits breast cancer resistant protein (BCRP). In a clinical study in healthy participants, the exposure of the BCRP substrate rosuvastatin increased approximately 2-fold following multiple doses of 61 mg tafamidis daily dosing.
In a clinical study (n=12) using healthy participants, the renal clearance of the OAT3 substrate rosuvastatin did not change following multiple doses of 61 mg tafamidis daily dosing. This suggests that any inhibition of OAT3 by tafamidis may not result in clinically significant interactions with OAT3 substrates.
The drugs listed in Table 3 are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction.
Table 3 - Established or Potential Drug-Drug Interactions
Source of Evidence
CYP3A4 substrates (e.g., midazolam, triazolam)
Tafamidis meglumine (20 mg) did not affect the PK of CYP3A4 substrate midazolam; the effect of 80 mg has not been studied.
In vitro, tafamidis meglumine induces CYP3A4 and may decrease exposure of substrates of this CYP enzyme at the higher dose of 80 mg. Caution should be exercised when VYNDAMAX (tafamidis) is co-administered with CYP3A4 substrates. Dose adjustment may be needed for these substrates.
Substrates of breast cancer resistant protein BCRP (e.g., methotrexate, rosuvastatin, imatinib)
In vitro, in vivo
Tafamidis inhibits BCRP systemically and in the GI tract and may increase exposure of substrates of this transporter.
Caution should be exercised when VYNDAMAX is co-administered with BCRP substrates. Dose adjustment may be needed for these substrates.
Substrates of organic anion transporters 1 (OAT1) and OAT3 (e.g., antiretroviral agents, diuretics, methotrexate, NSAIDs, olmesartan, pravastatin)
In vitro data indicate that tafamidis has a potential to inhibit OAT1 and may therefore decrease exposure of substrates of this transporter.
Caution should be exercised when VYNDAMAX is co-administered with OAT1 and OAT3 substrates. Dose adjustment may be needed for these substrates.
There is limited clinical evidence to suggest that any inhibition of OAT3 (specifically) by tafamidis may not result in clinically significant interactions with OAT3 substrates.
Concomitant administration of VYNDAMAX with a high fat, high calorie meal increased the Cmax by 32%, but did not affect the AUC. VYNDAMAX is to be administered with or without food.
No interaction studies have been performed evaluating the effect of herbal products on tafamidis.
Interactions with laboratory tests have not been established.
Tafamidis is a selective stabilizer of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate‑limiting step in the amyloidogenic process.
A TTR stabilization assay was utilized as a pharmacodynamic marker and assessed the stability of the TTR tetramer under denaturation conditions. Tafamidis stabilized both the wild‑type TTR tetramer and the tetramers of 14 TTR variants tested clinically after once‑daily dosing. Tafamidis also stabilized the TTR tetramer for an additional 25 variants tested ex vivo.
The 80 mg dose for VYNDAQEL (tafamidis meglumine) was selected based on maximal TTR % stabilization data from PK studies. The clinical relevance of a higher TTR stabilization is not known.
The recommended dose of VYNDAMAX (tafamidis) is 61 mg orally once daily.
At single dose of 400 mg, approximately 2.2 times the steady state peak plasma concentration (Cmax) at the recommended dose, tafamidis does not prolong the QTc interval to any clinically relevant extent.
Table 4 - Summary of Tafamidis Pharmacokinetic Parameters1 in Healthy Volunteers after a Single Dose of 1 x 61 mg Tafamidis Capsule.
N, n 2
4.00 (2.00 – 12.00)
3.00 (0.50 – 6.03)
After oral administration of VYNDAMAX (tafamidis) once daily, the maximum peak concentration (Cmax) is achieved at a median time (tmax) within 4 hours after dosing in the fasted state.
Concomitant administration of VYNDAQEL (tafamidis meglumine) with a high fat, high calorie meal decreased the Cmax by 15%, but did not affect the AUC. Concomitant administration of VYNDAMAX (tafamidis) with a high fat, high calorie meal increased the Cmax by 32%, but did not affect the AUC. VYNDAQEL and VYNDAMAX are to be administered with or without food.
VYNDAMAX and VYNDAQEL are not interchangeable on a per mg basis. (See 4.1 Dosing Considerations and 4.2 Recommended Dose and Dosage Adjustment)
Tafamidis is highly protein bound (>99%) in plasma. The apparent steady‑state volume of distribution is 18.5 liters in a 75 kg adult.
While there is no explicit evidence of biliary excretion of tafamidis in humans, based on preclinical data, it is suggested that tafamidis is metabolized by glucuronidation and excreted via the bile. This route of metabolism and excretion is likely in humans, as approximately 59% of the total administered dose is recovered in feces mostly as unchanged drug, and approximately 22% recovered in urine mostly as the glucuronide metabolite.
The mean half‑life of tafamidis is approximately 49 hours. The apparent oral clearance of tafamidis is 0.263 L/hr. The degree of drug accumulation at steady state after repeated tafamidis daily dosing is approximately 2.5‑fold greater than that observed after a single dose.
Special Populations and Conditions
Ethnic origin: No clinically significant differences in the pharmacokinetics of tafamidis were observed based on race/ethnicity (Caucasian and Japanese).
Pediatrics: Tafamidis has not been studied and is not indicated in this population.
Hepatic Insufficiency: Pharmacokinetic data indicated decreased systemic exposure (approximately 40%) and approximately 68% increase of total clearance (0.52 L/h versus 0.31 L/h) of tafamidis meglumine in subjects with moderate hepatic impairment (Child‑Pugh Class B) compared to healthy subjects. As TTR levels are lower in patients with moderate hepatic impairment than in healthy subjects, the exposure of tafamidis relative to the amount of TTR would be sufficient for stabilization of the TTR tetramer in these patients.
Exposure to VYNDAMAX was similar between subjects with mild hepatic impairment (Child-Pugh Class A) and healthy subjects.
The pharmacokinetics of VYNDAMAX in patients with severe hepatic impairment (Child-Pugh Class C) is unknown.
Renal Insufficiency: VYNDAMAX has not specifically been evaluated in patients with renal impairment. Limited data are available in patients with severe renal impairment (CrCl ≤30 mL/min).
Store VYNDAMAX at room temperature 15°C to 25°C.
There are no special handling instructions for this drug product.
Control #: 256231AUG 16, 2022
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at